Reference is made to Circio Holding ASA's (the "Company") outstanding
convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under
the Investment Agreement entered into between Atlas and the Company in March
2023.

Atlas has, by a notice of conversion, requested conversion of convertible bonds
with a nominal value of NOK 2,500,000 which, pursuant to the bond terms, are
convertible into 3,931,847 new shares in the Company at a conversion price of
NOK 0.6358.

The Company's share capital will accordingly be increased by NOK 2,359,108.20 by
the issuance of 3,931,847 new shares upon completion of the conversion by
registration of the share capital increase in the Norwegian Register of Business
Enterprises (Nw.: Foretaksregisteret). Following the conversion, the Company's
total share capital will be NOK 56,845,650.60 divided into 94,742,751 shares,
each with a nominal value of NOK 0.60.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine. Circio
has established a unique circular RNA (circRNA) vector expression platform for
novel DNA, RNA and viral therapeutics. The proprietary circVec technology is
based on a modular genetic cassette design for efficient biogenesis of
multifunctional circRNA inside cells, which can be deployed in multiple
therapeutic settings, including genetic medicine, cell therapy and chronic
disease. The circVec platform has demonstrated up to 15-fold enhanced and more
significantly more durable protein expression vs. classic mRNA vector systems
and has the potential to become a new gold-standard platform technology for
nucleic acid and viral therapeutics in the future. The circRNA R&D activities
are being conducted by the wholly owned subsidiary Circio AB based at the
Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.